Kingswood Wealth Advisors LLC Acquires New Holdings in Abrdn Life Sciences Investors (NYSE:HQL)

Kingswood Wealth Advisors LLC purchased a new position in Abrdn Life Sciences Investors (NYSE:HQL) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 12,211 shares of the company’s stock, valued at approximately $160,000.

Several other hedge funds also recently added to or reduced their stakes in HQL. Cetera Investment Advisers boosted its stake in Abrdn Life Sciences Investors by 6.9% in the 2nd quarter. Cetera Investment Advisers now owns 156,384 shares of the company’s stock worth $2,216,000 after purchasing an additional 10,137 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Abrdn Life Sciences Investors in the 2nd quarter worth approximately $154,000. Future Financial Wealth Managment LLC purchased a new position in Abrdn Life Sciences Investors during the 3rd quarter worth approximately $30,000. International Assets Investment Management LLC acquired a new stake in Abrdn Life Sciences Investors during the 3rd quarter valued at approximately $204,000. Finally, Stephens Inc. AR boosted its holdings in shares of Abrdn Life Sciences Investors by 7.6% in the 3rd quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after acquiring an additional 896 shares during the last quarter. 32.21% of the stock is owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Trading Up 0.5 %

NYSE:HQL opened at $14.23 on Monday. The company’s fifty day moving average price is $13.77 and its 200-day moving average price is $14.59. Abrdn Life Sciences Investors has a 1-year low of $12.76 and a 1-year high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Thursday, November 21st were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 14.05%. The ex-dividend date was Thursday, November 21st. This is a boost from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49.

Insider Transactions at Abrdn Life Sciences Investors

In related news, major shareholder Saba Capital Management, L.P. sold 11,674 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $14.12, for a total transaction of $164,836.88. Following the sale, the insider now owns 3,418,349 shares in the company, valued at approximately $48,267,087.88. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.